Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Patients treated for advanced neuroendocrine tumors (NETs) are at risk of disease progression after existing treatments, and the current options are often dependent on particular disease factors that ...

Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine ... PAC-1 enhances PNET cell death in cell culture and ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for gastrointestinal and genitourinary cancers such as prostate-specific membrane antigen ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine tumors (PNET). It's important to know the difference, because these two ...

The U.S. Food & Drug Administration has granted approval for a new drug to treat pancreatic neuroendocrine tumors, also called PNET or PanNET. “I am delighted that patients with pancreatic ...

well-differentiated pancreatic neuroendocrine tumors (pNET). Simultaneously, the drug was approved for adult and pediatric patients (12 years of age and older) with previously treated ...